0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VEGF110

VEGF110

Brief Information

Name:Vascular endothelial growth factor A
Target Synonym:Vascular endothelial growth factor A,VEGF,VEGFA,VPF,Vascular Endothelial Growth Factor A165,Vascular Endothelial Growth Factor,VEGF-A,MVCD1,Vascular permeability factor,Vascular Endothelial Growth Factor A121
Number of Launched Drugs:20
Number of Drugs in Clinical Trials:64
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
VE0-H5212 Human ActiveMax® Human VEGF110 Protein, Tag Free (HPLC-verified)
VE0-H5212-structure
VE0-H5212-sds
VE0-H5212-hplc
VE0-H5212-elisa_1

Part of Bioactivity data

VE0-H5212-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The EC50 for this effect is 5.06-11.59 ng/mL (Routinely tested).

VE0-H5212-HPLC
ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. ) HPLC images

The purity of ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) was greater than 90% as determined by SEC-HPLC.

VE0-H5212-ELISA
ActiveMax® Human VEGF110, Tag Free (HPLC-verified)ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) ELISA bioactivity

Immobilized ActiveMax® Human VEGF110, Tag Free (HPLC-verified) (Cat. No. VE0-H5212) at 0.05 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Cat. No. VE1-H5220) with a linear range of 4-63 ng/mL (QC tested).

Synonym Name

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

Background

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 110,121,145,165,183,189 and 206 amino acids in length are expressed in humans.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Bevacizumab biosimilar (Hetero Drugs) Approved Hetero Drugs Cizumab India Colorectal Neoplasms Hetero Drugs 2016-01-01 Colorectal Neoplasms Details
Bevacizumab biosimilar (Zydus Cadila) Approved Zydus Cadila Bryxta India Carcinoma, Non-Small-Cell Lung Zydus Cadila 2017-01-01 Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Elea) Approved Elea Lumiere Argentina Macular Degeneration Elea 2018-09-01 Macular Degeneration Details
Bevacizumab biosimilar (Biocon/Mylan) MYL-1402O Approved Biocon KRABEVA India Carcinoma, Renal Cell; Colorectal Neoplasms; Ovarian Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms null 2017-01-01 Ovarian Neoplasms; Carcinoma, Renal Cell; Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Biocad) BCD-021 Approved Biocad Avegra Russian Federation Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Biocad 2015-11-25 Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab Biosimilar (AXXO) Approved Axxo Russian Federation Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms Axxo 2013-01-01 Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Centus Biotherapeutics) FKB-238 Approved Fujifilm Kyowa Kirin Biologics Co Ltd Equidacent EU Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung Centus Biotherapeutics Ltd 2020-09-24 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Dr. Reddy's Laboratories) Approved Dr. Reddy’S Laboratories Ltd Versavo India Glioma; Carcinoma, Renal Cell; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms Dr. Reddy’S Laboratories Ltd 2019-01-01 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Glioma; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Neovasculgen PI-VEGF165 Approved Human Stem Cells Institute Neovasculgen Russian Federation Peripheral Arterial Disease Human Stem Cells Institute 2011-12-07 Peripheral Arterial Disease Details
Bevacizumab biosimilar (Samsung Bioepis) SB-8; SP-8 Approved Samsung Bioepis Aybintio EU Uterine Cervical Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Carcinoma, Renal Cell Samsung Bioepis Nl Bv 2020-08-19 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Pfizer) PF-6439535; PF-06439535 Approved Pfizer Inc Zirabev United States Peritoneal Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms Pfizer Inc 2019-02-14 Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Intas Pharmaceuticals) Approved Intas Biopharmaceuticals Bevatas Carcinoma, Non-Small-Cell Lung Details
Ziv-aflibercept AVE-0005; BAY-865321 Approved Sanofi, Regeneron Pharmaceuticals Inc Zaltrap Japan Colorectal Neoplasms Sanofi 2012-08-03 Solid tumours; Ovarian Neoplasms; Lung Diseases; Ascites; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Lung Neoplasms; Neoplasm Metastasis Details
Bevacizumab R-435; G180CL; G180CU; G180DL; RG-435; NSC-704865; RO-4876646 Approved Genentech Inc 安维汀, Avastin Mainland China Glioblastoma Roche Pharma (Schweiz) Ag 2004-02-26 Colorectal Neoplasms; Carcinoma, Hepatocellular; Macular Degeneration; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Glioma; Peritoneal Neoplasms; Ovarian Neoplasms; Sarcoma; Brain Neoplasms; Breast Neoplasms; Multiple Myeloma; Carcinoma, Ovarian Epithelial; Glioblastoma; Carcinoma, Renal Cell; Liver Neoplasms Details
Ranibizumab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Razumab India Macular Degeneration Intas Biopharmaceuticals 2015-01-01 Macular Degeneration Details
Bevacizumab biosimilar (Innovent Biologics) IBI-305; IBI305; IBI 305 Approved Innovent Biologics(Suzhou) Co Ltd 达攸同 Mainland China Carcinoma, Hepatocellular Innovent Biologics(Suzhou) Co Ltd 2020-06-17 Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Ranibizumab RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab; rhuFab-V2; Y-0317; RFB-002; RG-6321 Approved Novartis Pharma Ag, Genentech Inc Lucentis, 诺适得 Japan Diabetic macular oedema Novartis Pharma Ag 2006-06-30 Macular Edema; Vision Disorders; Neovascularization, Pathologic; Glaucoma, Neovascular; Myopia, Degenerative; Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Retinal Degeneration; Macular Degeneration; Choroidal Neovascularization; Retinal Vein Occlusion; Diabetes Mellitus; Diabetic Retinopathy; Myopia; Retinopathy of Prematurity Details
Bevacizumab biosimilar (Boan Biopharma) LY-01008 Approved Shandong Boan Biotechnology Co Ltd 博优诺 Mainland China Glioblastoma Shandong Boan Biotechnology Co Ltd 2021-05-07 Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Brolucizumab XSZ53G39H5 (UNII code); RTH-258; AL-86810; DLX-1008; ESBA-1008 Approved Novartis Pharma Ag, Alcon Beovu Japan Macular Degeneration Novartis Pharma Ag 2019-10-07 Macular Edema; Vision Disorders; Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Retinal Degeneration; Macular Degeneration; Diabetic Retinopathy; Diabetes Mellitus; Retinal Vein Occlusion; Choroidal Neovascularization Details
Bevacizumab biosimilar (Allergan/Amgen) ABP-215 Approved Amgen Inc Mvasi Japan Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell Daiichi Sankyo Co Ltd 2017-09-14 Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Aflibercept BAY-865321; BAT-86-5321 Approved Regeneron Pharmaceuticals Inc, Bayer Ag Eylea Mainland China Macular Degeneration; Macular Edema Bayer Australia Ltd 2011-11-18 Wet Macular Degeneration; Retinopathy of Prematurity; Diabetic Retinopathy; Diabetes Mellitus; Neoplasm Metastasis; Macular Degeneration; Retinal Vein Occlusion; Retinal Degeneration; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic macular oedema; Prostatic Neoplasms; Retinal Diseases; Myopia, Degenerative; Neoplasms; Glaucoma, Neovascular; Diabetes Mellitus, Type 2; Macular Edema Details
Conbercept FP-3; KH-902 Approved Chengdu Kanghong Biotechnologies Co Ltd 朗沐, Langmu Mainland China Macular Degeneration Chengdu Kanghong Biotechnologies Co Ltd 2013-11-27 Macular Edema; Vision Disorders; Wet Macular Degeneration; Diabetic macular oedema; Retinoblastoma; Macular Degeneration; Corneal Neovascularization; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetes Mellitus Details
Bevacizumab biosimilar (mAbixience) MB02; BEVZ-92 Approved Mabxience EU Peritoneal Neoplasms; Fallopian Tube Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms null, Stada Arzneimittel Ag 2021-03-26 Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) BP-102 Approved Jiangsu Hengrui Medicine Co Ltd Mainland China Rectal Neoplasms; Carcinoma, Non-Small-Cell Lung Suzhou Suncadia Biopharmaceuticals Co Ltd 2021-06-22 Solid tumours; Rectal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Varisacumab R-84; GNR-011; AT-001-IBCG Phase 3 Clinical Peregrine, Ut Southwestern Medical Center Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
MP-0250 MP-0250 Phase 2 Clinical Molecular Partners Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Reliance Life Sciences) R-TPR-023 Phase 3 Clinical Reliance Life Sciences Colorectal Neoplasms Details
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) HD-204 Phase 3 Clinical Hanwha Biologics Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ranibizumab biosimilar (Xbrane) Phase 3 Clinical Xbrane Biopharma Macular Degeneration Details
Ranibizumab biosimilar (Pfenex) PF-582 Phase 2 Clinical Pfenex Macular Degeneration Details
Ranibizumab biosimilar (Reliance Life Sciences Group) R-TPR-024 Phase 3 Clinical Reliance Life Sciences Macular Degeneration Details
Intravitreal ranibizumab (Sultan Qaboos University) Phase 2 Clinical Sultan Qaboos University Retinal Dysplasia Details
ASC-06 ALN-VSP; ALN-VSP01; ALN-VSP02; ASC-06 Phase 1 Clinical Alnylam Pharmaceuticals Inc Liver Neoplasms; Neoplasms Details
Ranibizumab biosimilar (Shanghai United Cell Biotechnology) Phase 1 Clinical Shanghai United Cell Biotechnology Co Ltd Macular Edema Details
Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药(CinnaGen)) Phase 3 Clinical Cinnagen Macular Degeneration Details
Ranibizumab biosimilar (Senju) GBS-007 Phase 3 Clinical Senju Pharmaceutical Co Ltd Macular Degeneration Details
CLS-1002 CLS-1002 Phase 1 Clinical Clearside Biomedical Macular Degeneration Details
Aflibercept biosimilar (Amgen) Phase 2 Clinical Amgen Inc Macular Degeneration Details
LMG-324 LMG-324 Phase 2 Clinical Alcon Macular Degeneration Details
Bevacizumab biosimilar (Celltrion) CT-16; CTP-16 Phase 3 Clinical Celltrion Adenocarcinoma of Lung; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LHA-510 LHA-510 Phase 2 Clinical Alcon Macular Degeneration Details
Bevacizumab biosimilar (Synermore Biologics) SYN-050 Phase 1 Clinical Lonn Ryonn Pharma Ltd, Xingmeng Biotechnology (Beijing) Co Ltd Neoplasms Details
Bevacizumab biosimilar (Oncobiologics) ONS-1045; ONS-5010 Phase 3 Clinical Outlook Therapeutics Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration Details
Aflibercept biosimilar (Samsung Bioepis) SB-15 Phase 3 Clinical Samsung Bioepis Macular Degeneration Details
OB-318 OB-318 Phase 1 Clinical Oneness Biotech Neoplasms; Carcinoma, Hepatocellular Details
Bevacizumab biosimilar (AryoGen Biopharma) Phase 3 Clinical Aryogen Biopharma Colorectal Neoplasms Details
Bevacizumab biosimilar (JHL Biotech) JHL-1149 Phase 1 Clinical JHL Biotech Ovarian Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) Phase 1 Clinical Pepscan Systems Colorectal Neoplasms Details
Aflibercept biosimilar (Momenta/Mylan) M-710; MYL-1701P Phase 3 Clinical Mylan, Momenta Diabetic macular oedema Details
Aflibercept/Nesvacumab REGN 910-3 Phase 2 Clinical Regeneron Pharmaceuticals Inc Diabetic macular oedema; Macular Degeneration Details
Bevacizumab biosimilar (Alphamab/R-Pharm) RPH-001 Phase 3 Clinical Suzhou Alphamab Co Ltd, R-Pharm Colorectal Neoplasms Details
Ranibizumab biosimilar (CJSC Generium) GNR-067 Phase 1 Clinical Cjsc Generium Macular Degeneration Details
Ranibizumab biosimilar (Formycon/Bioeq) FYB-201 Phase 3 Clinical Formycon Macular Degeneration Details
Bevacizumab biosimilar (Tanvex BioPharma) TX-16 Phase 1 Clinical Tanvex Biopharma Colorectal Neoplasms Details
Bevacizumab biosimilar (Cipla BioTec) CBT-124 Phase 3 Clinical Cipla Gmbh Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Gedeon Richter) Phase 1 Clinical Gedeon Richter Plc Neoplasms Details
AAV.7m8-aflibercept (Adverum Biotechnologies) ADVM-022 Phase 1 Clinical Adverum Biotechnologies Macular Degeneration Details
Ranibizumab biosimilar (Lupin) LUBT-010 Phase 3 Clinical Rubin Ltd Macular Degeneration Details
AZD-8601 AZD-8601; mRNA-AZD-8601 Phase 2 Clinical Astrazeneca Pharmaceutical Co Ltd, Modernatx Heart Failure Details
Dilpacimab ABT-165; DVD-Ig ABT-165 Phase 2 Clinical Abbvie Inc Solid tumours; Neoplasms; Colorectal Neoplasms Details
Vanucizumab RG-7221; RO-5520985; B800Z06O8K (UNII code) Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Neoplasms; Colorectal Neoplasms Details
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) LY-09004 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd Diabetic macular oedema; Macular Degeneration Details
Bevacizumab biosimilar (Hualan Biological Engineering) WBP-264 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Aflibercept biosimilar (Mabwell) 9MW0813 Phase 1 Clinical Diabetic macular oedema Details
Aflibercept biosimilar (Qilu Pharmaceutical) QL-1207 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Diabetic macular oedema; Macular Degeneration Details
Ranibizumab biosimilar (Qilu Pharmaceutical) BCD-300; QL-1205 Phase 3 Clinical Qilu Pharmaceutical Co Ltd, Biocnd Macular Degeneration Details
Bevacizumab biosimilar (Beijing Mabworks Biotech) MIL-60 Phase 3 Clinical Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
TAB-008 TAB-008; TOT-102 Phase 3 Clinical Tot Biopharm Co Ltd Carcinoma, Non-Small-Cell Lung Details
Recombinant anti-VEGF humanized monoclonal antibody (Jiangsu Aosaikang Pharmaceutical) ASK-1202; AMD-B; AK-3008 Phase 3 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bevacizumab biosimilar (Eastern Biotech) JY-028 Phase 1 Clinical Beijing Eastern Biotech Co Ltd Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ziv-aflibercept biosimiliar (Boan Biopharma) LY-01012 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd Wet Macular Degeneration; Colorectal Neoplasms; Macular Degeneration Details
BI-695502 BI-695502 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) CKD-701 Phase 3 Clinical Chong Kun Dang Pharmaceutical Corp Macular Degeneration Details
Ethyl acetate extract ALS-L1023 Phase 2 Clinical Angiolab Inc Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Macular Degeneration Details
Muparfostat sodium PI-88 Phase 3 Clinical Australian National University Liver Neoplasms; Solid tumours; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Sevacizumab TK-001; APX-003; BD-0801; EPI-0030; SIM-BD-0801 Phase 3 Clinical Epitomics Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration Details
Aflibercept biosimilar (Sam Chun Dang Pharm) SCD-411 Phase 3 Clinical Sam Chun Dang Pharm Co Ltd Macular Degeneration Details
RC-28 RC28-E; RC-28-E; RC-28 Phase 2 Clinical Rc Biotechnologies Ltd Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy Details
Y-400 Y-400 Clinical Wuhan Yzy Biopharma Details
Ranibizumab biosimilar (Samsung Bioepis) SB-11 Phase 3 Clinical Samsung Bioepis Macular Degeneration Details
Bevacizumab biosimilar (CTTQ Pharma) TQ-B2302 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Ovarian Neoplasms; Glioblastoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
PTC-299 PTC-299 Phase 3 Clinical Ptc Therapeutics Inc Pneumonia; Esophageal Neoplasms; Neurofibromatoses; Coronavirus Disease 2019 (COVID-19); Neurofibromatosis 2; Breast Neoplasms; Coronavirus Infections; Leukemia, Myeloid, Acute; Sarcoma, Kaposi Details
Aflibercept Biosimilar (Clover Biopharmaceuticals) SCB-420 Phase 1 Clinical Sichuan Sanyecao Bio-Pharmaceutical Co Ltd Diabetic macular oedema; Macular Degeneration Details
Bevacizumab (Beijing Science Sun) K-11; K11 Phase 2 Clinical Beijing Science Sun Pharmaceutical Co Ltd Glioblastoma; Neoplasms; Glioma Details
CT-P42 CT-P42 Phase 3 Clinical Celltrion Diabetic macular oedema Details
SCT-501(National Cancer Institute) SCT-501 Phase 2 Clinical National Cancer Institute Kidney Neoplasms Details
Eylea Biosimilar (Alteogen) ALT-L9 Phase 1 Clinical Alteogen Inc, Kissei Pharmaceutical Macular Degeneration Details
FYB-203 FYB-203 Phase 3 Clinical Formycon Macular Degeneration Details
Bevacizumab biosimilar (Shanghai Henlius Biotech) HLX-04; HLX04-O Phase 3 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours; Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Macular Degeneration Details

This web search service is supported by Google Inc.

totop